After some lengthy delays, Sanofi gets the FDA's OK for a rare disease drug
More than 2 years after Sanofi claimed an early pivotal win for its newly-acquired rare disease drug sutimlimab, and more than a year since the FDA handed back their initial application due to unexplained manufacturing issues, the pharma giant has bounced back with the approval late on Friday.
Sanofi, which is undergoing both a facelift as well as a restructuring under CEO Paul Hudson, cheered the news that regulators in the US have cleared the drug for cold agglutinin disease, an affliction that triggers a rare form of anemia in patients.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.